KOSDAQBiotech & Pharma303810

DongKook Life Science

₩1,674▲ 1.21%2026-11-18 close
Market Cap
₩53.5B
Turnover
₩200M
Volume
110K
Shares out.
32M
PER
25.9×
PBR
0.4×
EPS
₩64
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Exiting Diagnostics to Focus on Contrast Agents

DongKook Life Science swung to an operating loss in Q3 2026 and is restructuring by exiting its diagnostic equipment business to concentrate on contrast agents and overseas registrations.

  1. 1

    FY2025 disclosed revenue was KRW 130.3 billion and operating profit KRW 13 billion, with operating margin at 10.0%, up from 7.1% in 2023.

  2. 2

    Q3 2026 showed an operating loss of KRW 1.59 billion and a net loss attributable to controlling shareholders of KRW 506 million, after Q2 2026 operating profit of KRW 21.88 million.

  3. 3

    On November 16, 2026, the company announced the exit of its diagnostic equipment (ME) business and a planned rename to DK Luonix, without disclosing the sales decline or exit costs.

  4. 4

    Overseas growth depends on country-by-country registrations and pending EU GMP and MRI CEP certifications, and the company expects gradual results from overseas sales starting in 2028.

  5. 5

    Hana Securities, in a report carried on November 17, 2026, estimated 2026 revenue at KRW 102 billion and operating profit at about KRW 1 billion.

02

Business structure

DongKook Life Science is a bio-pharmaceutical company centered on contrast agents for diagnostic imaging.

In 2025, segment sales were KRW 88.1 billion for the contrast agent division and KRW 42.2 billion for the MEMD (medical equipment and medical devices) division, and the MEMD division grew 14.36% year on year, according to the company's April 2, 2026 announcement.

Its flagship products are an X-ray contrast agent and an MRI contrast agent. A Dailypharm report says the company ranks first in domestic contrast agent market share and has an export network spanning 17 countries, including Europe, Japan and Southeast Asia.

The company has pointed to its vertically integrated in-house production as the foundation for global expansion. It attributed 2025 results to the market establishment of new contrast agent products and expansion into healthcare areas such as medical devices and medical AI.

The ME business, which distributes and sells diagnostic imaging equipment, runs alongside the contrast agent business, but how much of the KRW 42.2 billion MEMD sales it accounts for has not been disclosed.

On November 16, 2026, the company announced it would exit the ME business, citing weak sales after CT and MRI insurance fee adjustments shrank the diagnostic equipment market. The company says the exit will reduce fixed costs and operating burdens. It did not disclose the size of the sales decline or the exit costs.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩29.4B₩4.3B14.5%
2025Q4₩31B₩2.5B7.9%
2026Q1₩33.1B₩3.4B10.4%
2026Q2₩24.3B₩21,875,3690.1%
2026Q3₩26.5B-₩1.6B−6.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩120.2B₩8.5B₩4.2B7.1%6.1%160.7%
2024₩131.8B₩11.9B₩2.2B9.0%2.1%82.1%
2025₩130.3B₩13B₩8.7B10.0%6.6%65.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a disclosed annual basis, revenue was KRW 120.2 billion in 2023, KRW 131.8 billion in 2024 (up 9.7% year on year) and KRW 130.3 billion in 2025 (down 1.1% year on year). Among 2023 to 2025, 2024 was the largest year for revenue and 2023 the smallest.

Operating profit was KRW 8.53 billion in 2023, KRW 11.9 billion in 2024 (up 39.7%) and KRW 13 billion in 2025 (up 9.5%), rising for two consecutive years from 2024 to 2025. Operating margin climbed from 7.1% in 2023 to 9.0% in 2024 and 10.0% in 2025.

In 2025 revenue fell, yet margin improvement still lifted operating profit. The company attributed the 2025 results to structural improvement focused on profitability and cost efficiency.

Net profit attributable to controlling shareholders was KRW 4.17 billion in 2023, KRW 2.24 billion in 2024 (down 46.1%) and KRW 8.66 billion in 2025 (up 285.7%), and net profit including non-controlling interests was disclosed at the same amounts.

The 2024 decline and 2025 rebound did not track operating profit, and one press report pointed to lower interest expense after the conversion of redeemable convertible preferred shares as a driver of net profit growth.

Operating cash flow was KRW -4.61 billion in 2023, KRW 11.5 billion in 2024 and KRW 434 million in 2025.

On a quarterly basis, Q3 2025 revenue was KRW 29.4 billion with operating profit of KRW 4.28 billion, Q4 2025 revenue was KRW 31 billion with KRW 2.45 billion, and Q1 2026 revenue was KRW 33.1 billion with KRW 3.44 billion.

Q2 2026 revenue fell 26.7% quarter on quarter to KRW 24.3 billion, and operating profit shrank to KRW 21.88 million. Q3 2026 revenue was KRW 26.5 billion, up 9.3% quarter on quarter but down 9.9% year on year, and the company posted an operating loss of KRW 1.59 billion.

The company said the ME business weakness and restructuring were reflected in Q3 2026 results. Net losses attributable to controlling shareholders were KRW 888 million in Q2 2026 and KRW 506 million in Q3 2026, making two consecutive loss-making quarters.

Net profit attributable to controlling shareholders over the last four quarters (Q4 2025 to Q3 2026) totaled KRW 2.06 billion.

05

Industry analysis

DongKook Life Science's ME business was tied directly to the operating environment of the CT and MRI diagnostic equipment market. According to the company, the operating environment for diagnostic equipment weakened after CT and MRI insurance fee adjustments in Q2 2026, and ME sales stayed weak as a result.

Because insurance fee policy changed demand for equipment-driven businesses, the policy environment is a key variable for the sector. The company has described its contrast agent business as operating in synergy with the ME business, and contrast agent division sales were KRW 88.1 billion in 2025.

A Dailypharm report said the company holds the No. 1 position in domestic contrast agent market share, but the basis for that share and competitors' contrast agent sales were not presented.

On profitability, the same report said the company's 2024 operating margin was higher than those of several large and mid-sized pharmaceutical companies it cited.

Overseas, EU GMP and an MRI contrast agent CEP certification are in progress, and country-by-country registration is a precondition for expanding sales areas. In healthcare, the company has presented a strategy of expanding into medical devices and medical AI.

A partner company, Inventera, listed on KOSDAQ on April 2, 2026, and the two are expected to create synergies around the contrast agent business. The company has not presented a timeline for when the diagnostic equipment market will recover.

06

Outlook

The most concrete medium-term target the company has presented is gradual overseas sales results starting in 2028. The company said registrations and approvals for its key products are proceeding by country as planned.

EU GMP and an MRI contrast agent CEP certification are also being pursued, and the company plans to widen sales areas and local partnerships in each country once approval is complete. The global business is currently in the market-entry preparation stage, and a gradual contribution to results from 2028 was reported.

According to the company, exiting the ME business should reduce fixed costs and operating burdens and change the earnings structure. However, the exit costs and the size of the sales decline have not been disclosed, so the size of the effect can be checked in the 2026 annual report.

The company is pursuing a rename to DK Luonix and says it will expand into global healthcare, building on its diagnostic imaging expertise and vertically integrated production. In a November 17, 2026 report, Hana Securities estimated 2026 revenue at KRW 102 billion and operating profit at KRW 1 billion.

These figures are a brokerage estimate and not company guidance. The 2026 annual results will be confirmed in the 2026 annual report, and any gap versus the estimate will be visible then.

07

Valuation

PER
25.9×
PBR
0.4×
ROE
1.6%
EPS
₩64
BPS
₩4,198
Dividend per share
₩0

Because trailing earnings over the last four quarters totaled only KRW 2.06 billion, the price-to-earnings multiple is highly sensitive to changes in profit. Measured against shareholders' equity of KRW 131.4 billion at year-end 2025, the price-to-book ratio sits in a range below book value.

The dividend yield is below the industry average. The debt-to-equity ratio fell from 160.7% in 2023 to 65.7% in 2025, indicating an improving capital structure. However, operating cash flow in 2025 was only KRW 434 million, so the conversion of profit into cash was limited.

If 2026 operating profit reaches about KRW 1 billion, as Hana Securities estimated, earnings-based multiples could shift considerably with changes in that estimate. The multiple and book-value comparisons will depend on the confirmed 2026 annual results and progress in overseas business.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Margin improvement trend

Operating margin rose from 7.1% in 2023 to 9.0% in 2024 and 10.0% in 2025, and 2025 operating profit reached KRW 13 billion, up 9.5%. Operating cash flow stayed positive in both 2024 and 2025. The debt-to-equity ratio fell from 160.7% in 2023 to 65.7% in 2025, easing financial burden.

Core contrast agent franchise

The contrast agent division generated KRW 88.1 billion in 2025 and formed the center of company revenue, and the company said new contrast agent products have gained market acceptance. A Dailypharm report cited the company as the No. 1 domestic contrast agent player.

Its export network across 17 countries, including Europe, Japan and Southeast Asia, is also cited as a strength.

Overseas registrations and restructuring

The company said country-by-country registrations and approvals for key products are proceeding as planned, and it is pursuing EU GMP and an MRI contrast agent CEP certification.

Exiting the weak ME business to reduce fixed costs and operating burdens is an attempt to shift the earnings structure toward contrast agents and core pharmaceuticals. The company expects overseas sales results to emerge gradually from 2028.

09

Bear factors

Swing to losses in Q3 2026

Q3 2026 posted an operating loss of KRW 1.59 billion and a net loss attributable to controlling shareholders of KRW 506 million. Q2 2026 operating profit had already fallen to KRW 21.88 million, and the company has two consecutive loss-making quarters from Q2 to Q3 2026.

Net profit attributable to controlling shareholders over the last four quarters totaled only KRW 2.06 billion, a thin earnings base.

Uncertainty around the ME exit

Weak ME sales continued after CT and MRI insurance fee adjustments, and the company has not disclosed the exit costs or the size of the sales decline. The company says the effects were partly reflected in Q3 2026 results, but no completion date or additional costs have been presented. The scale of the business remaining after the exit is also not separated in the disclosures.

Gap before overseas earnings

Hana Securities' estimate of KRW 102 billion in 2026 revenue and KRW 1 billion in operating profit sits well below the disclosed 2025 results. With overseas sales expected only from 2028, the domestic contrast agent business will continue to carry earnings until then. Contrast agent sales are the key variable for results during this period.

10

Risk factors

Earnings volatility

Quarterly revenue and operating profit swung sharply in Q2 and Q3 2026. Results depend on external policy variables such as CT and MRI insurance fees, which is a risk factor. If operating margin fails to hold near the 10.0% reached in 2025, the earnings recovery could reverse.

Timing of overseas business

The company expects overseas sales results to emerge gradually from 2028. However, the timeline could slip depending on the pace of country-by-country approvals and local partnerships. The company itself says it is still in the market-entry preparation stage.

Share supply overhang

A press report said the financial investor Life Value Up Private Equity Partnership sold 983,066 shares (31.28%) in five transactions after the listing. The company's market capitalization is relatively small, so large trades could have an outsized effect on share price movements. How interest shifts during the rename is another variable.

11

What to watch next

  1. Around January 2027 (estimate based on prior-year timing)

    Preliminary FY2026 results. Whether operating margin holds at 10.0% and how the Q3 2026 loss is reflected in the full-year figures are the points to check.

  2. By March 31, 2027

    Filing of the 2026 annual report. The confirmed annual net profit attributable to controlling shareholders and whether ME exit-related items are reflected are the key points of the next periodic report.

  3. By May 15, 2027

    Q1 2027 quarterly report, the first quarter after the ME exit, which will show how the diagnostic equipment share of revenue has changed.

  4. From 2028

    The period in which the company expects overseas sales expansion to begin showing results. Before then, whether the EU GMP and MRI contrast agent CEP certifications are obtained is the interim checkpoint.

  5. Date not yet set

    Completion of the planned rename to DK Luonix and related filings. Once the name changes, disclosures and business descriptions will use the new name, so later filings should be tracked under it.

12

Overall view

DongKook Life Science lifted its operating margin from 7.1% in 2023 to 10.0% in 2025, showing a profitability improvement trend. Net profit attributable to controlling shareholders rebounded to KRW 8.66 billion in 2025, with non-operating factors such as lower interest expense cited by the company and press reports.

However, weak diagnostic equipment sales overlapped in Q2 and Q3 2026, leading to an operating loss and a net loss, and the last four quarters totaled only KRW 2.06 billion in net profit attributable to controlling shareholders.

The company has moved to exit the ME business, which shrank after CT and MRI insurance fee adjustments, and to focus resources on contrast agents, core pharmaceuticals and overseas registrations.

The company expects overseas sales to emerge gradually from 2028, so there is a wide gap between near-term results and the medium-term strategy. Strengths cited include the contrast agent market position, the export network and an improved capital structure.

Weaknesses cited include two consecutive loss-making quarters, undisclosed exit costs and share supply pressure. Hana Securities' estimates sit below the disclosed 2025 results, so the gap versus the confirmed 2026 annual figures is the next point to check.

The 2026 annual report will show full-year operating margin, the effect of the ME exit and progress on overseas registrations.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. localsegye.co.kr
  2. cnbnews.com
  3. fintechtimes.co.kr
  4. zdnet.co.kr
  5. pinpointnews.co.kr
  6. econovill.com
  7. kpanews.co.kr
  8. mydaily.co.kr
  9. medipana.com
  10. news.nate.com
  11. medicaltimes.com
  12. goinsider.kr
  13. news.nate.com
  14. newspim.com
  15. m.news.nate.com
  16. m.news.nate.com
  17. thepowernews.co.kr
  18. m.news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis